An agent-based model of prostate Cancer bone metastasis progression and response to Radium223.

ABSTRACT:

Background

Bone metastasis is the most frequent complication in prostate cancer patients and associated outcome remains fatal. Radium223 (Rad223), a bone targeting radioisotope improves overall survival in patients (3.6 months vs. placebo). However, clinical response is often followed by relapse and disease progression, and associated mechanisms of efficacy and resistance are poorly understood. Research efforts to overcome this gap require a substantial investment of time and resources. Computational models, integrated with experimental data, can overcome this limitation and drive research in a more effective fashion.

Methods

Accordingly, we developed a predictive agent-based model of prostate cancer bone metastasis progression and response to Rad223 as an agile platform to

SUBMITTER: Casarin S 

PROVIDER: S-EPMC7325060 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature